[Skip to Content]
[Skip to Content Landing]
April 30, 1960


Author Affiliations

Seaside Memorial Hospital of Long Beach Long Beach, Calif.

JAMA. 1960;172(18):2112. doi:10.1001/jama.1960.03020180122029

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  The abstract of the report "Further Experience with Oral Therapy in Diabetes" (J. A. M. A.172:876 [Feb. 20] 1960) merits comment in view of the statement in it that "these findings suggest that metaheximide is a well-tolerated hypoglycemic agent." In a form letter for mailing list distribution in June, 1959, W. F. Wenner, M.D., of the Upjohn Company, stated the following: "On May 10 we terminated all clinical trials [with metaheximide], for evidence then left little reasonable doubt as to the causative relationship between the use of this agent and the occurrence of jaundice associated with hepatic parenchymal necrosis."A case of severe liver damage that occurred after the administration of metaheximide was recently reported (Mach and others: New England J. Med.261:438 [Aug. 27] 1959, abstracted in J. A. M. A.171:2366 [Dec. 26] 1959). In this article the authors comment on

First Page Preview View Large
First page PDF preview
First page PDF preview